Drug Action
Triamcinolone exerts predominantly glucocorticoid effects with minimal mineralcorticoid effect.
Source page 1294
Loading InternPractice…
Individual generic drug information
Extracted information for Triamcinolone acetonide only.
Triamcinolone exerts predominantly glucocorticoid effects with minimal mineralcorticoid effect.
Source page 1294
Prophylaxis and treatment of allergic rhinitis ▶BY INTRANASAL ADMINISTRATION ▶Child 6–11 years: 55 micrograms once daily, dose to be sprayed into each nostril, increased if necessary to 110 micrograms once daily, dose to be sprayed into each nostril; reduced to 55 micrograms once daily, dose to be sprayed into each nostril, reduce dose when control achieved; maximum duration of treatment 3 months ▶Child 12–17 years: 110 micrograms once daily, dose to be sprayed into each nostril, reduced to 55 micrograms once daily, dose to be sprayed into each nostril, reduce dose when control achieved ▶Adult: 110 micrograms once daily, dose to be sprayed into each nostril, reduced to 55 micrograms once daily, dose to be sprayed into each nostril, reduce dose when control achieved
Source pages 1294, 1295
▶In adults Preparations of triamcinolone acetonide can be sold to the public for nasal administration as a non- pressurised nasal spray if supplied for the symptomatic treatment of seasonal allergic rhinitis in adults over 18 years, subject to maximum daily dose of 110 micrograms per nostril for maximum 3 months, and a pack size of 3.575 mg.
Source page 1295
Extracted information for Triamcinolone acetonide only.
→Appendix 1: corticosteroids
Source page 1295
Extracted information for Triamcinolone acetonide only.
There can be variation in the licensing of different medicines containing the same drug. Spray EXCIPIENTS: May contain Benzalkonium chloride, disodium edetate, polysorbates ▶Nasacort (Sanofi) Triamcinolone acetonide 55 microgram per 1 dose Nasacort 55micrograms/dose nasal spray | 120 dose P £7.39 DT = £7.39 Oropharynx Dry mouth Treatment of dry mouth Overview Dry mouth (xerostomia) may be caused by drugs with antimuscarinic (anticholinergic) side-effects (e.g. antispasmodics, tricyclic antidepressants, and some antipsychotics), by diuretics, by irradiation of the head and neck region or by damage to or disease of the salivary glands. Patients with a persistently dry mouth may develop a burning or scalded sensation and have poor oral hygiene; they may develop increased dental caries, periodontal disease, intolerance of dentures, and oral infections (particularly candidiasis). Dry mouth may be relieved in many patients by simple measures such as frequent sips of cool drinks or sucking pieces of ice or sugar-free fruit pastilles. Sugar-free chewing gum stimulates salivation in patients with residual salivary function. Artificial saliva can provide useful relief of dry mouth. A properly balanced artificial saliva should be of a neutral pH and contain electrolytes (including fluoride) to correspond approximately to the composition of saliva. The acidic pH of some artificial saliva products may be inappropriate. Of the proprietary preparations, Biotène Oralbalance ® gel or Xerotin ® can be used for any condition giving rise to a dry mouth. BioXtra ®, Glandosane ®, Saliva Orthana ®, and Saliveze ®, have ACBS approval for dry mouth associated only with radiotherapy or sicca syndrome. Salivix ® pastilles, which act locally as salivary stimulants, are also available for any condition leading to a dry mouth and SST tablets may be prescribed for dry mouth in patients with salivary gland impairment (and patent salivary ducts). Pilocarpine tablets p. 1274 are licensed for the treatment of xerostomia following irradiation for head and neck cancer and for dry mouth and dry eyes (xerophthalmia) in Sjögren’s syndrome. They are effective only in patients who have some residual salivary gland function, and therefore should be withdrawn if there is no response. LUBRICANTS
Source page 1295
Filter the extracted dose blocks for this individual drug.
First line only; read the complete Indications and dose section above.
55 micrograms once daily, dose to be
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 1294
First line only; read the complete Indications and dose section above.
110 micrograms once daily, dose to be
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 1295
First line only; read the complete Indications and dose section above.
110 micrograms once daily, dose to be sprayed
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 1295